SPOTLIGHT: FDA asks for data on asthma meds

The FDA has asked the makers of several beta agonist drugs for more data from clinical trials so it can "further evaluate the safety" of the drugs when used to treat asthma. Once the data is collected, the agency will convene an advisory panel to evaluate the safety risks. Back in 2005, FDA alerted healthcare professionals and patients that the drugs might increase the risk of worsened wheezing in some patients. Release

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.